Business
David Jiménez Joins Moderna As U.S. General Manager
CAMBRIDGE, MA / ACCESSWIRE / November 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and
About this update from Moderna, Inc.
[{"type":"text","content":"CAMBRIDGE, MA / ACCESSWIRE / November 17, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the appointment of David Jiménez as General Manager, United States, effective November 21, 2022. Mr. Jiménez will be responsible for commercial efforts in the United States, reporting to Arpa Garay, Moderna's Chief Commercial Officer.\"David has significant experience in leading major pharmaceutical franchises and bringing transformational products to patients,\" said Ms. Garay. \"His expertise will be invaluable as we transition to a commercial vaccine market in the U.S., and as we work to advance new candidates in 2023 and beyond. I'm excited to collaborate with him during this pivotal time for our business.\"Prior to Moderna, Mr. Jiménez spent two decades at Johnson & Johnson in a variety of leadership roles in the Medical Devices, Consumer Health and Pharmaceutical sectors, across four continents. In his most recent role, Mr. Jiménez served as President for Janssen Immunology, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, leading the unit's $10+ billion U.S. Immunology franchise. He also previously led Janssen's Pulmonary Hypertension U.S. organization, for in-market brands, including two which achieved blockbuster status under his leadership. Mr. Jiménez is a pharmacist, with a Doctorate in Pharmacy from the University of Alcala and a Master of Business Administration from the Instituto de Empresa, both in Madrid. He also recently completed the Advance Management Program at Harvard Business School in Boston.\"I've long admired Moderna for both their pioneering approach to mRNA technology and ability to rapidly advance science to bring transformative medicines to patients,\" said Mr. Jiménez. \"This is already a terrific organization, with a talented and growing commercial team in the U.S., and a highly impactful vaccine that continues to play a significant role in addressing the COVID-19 pandemic. I am thrilled to be joining Moderna and look forward to expanding its presence within the U.S.\"About ModernaIn 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics acros...